Clinical trials: Pembrolizumab
Pleural Malignant Mesothelioma
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
This phase I trial studies the side effects and best way to give pembrolizumab after radiation therapy in treating patients with pleural malignant mesothelioma.
- Trial name
- NCT02959463
- Testing
- Laboratory Biomarker Analysis, Palliative Radiation Therapy, Pembrolizumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric Cancer
Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
This study is an open-label, single arm, phase II trial the efficacy and safety of pembrolizumab + CapeOx (HER2 negative ARM) or pembrolizumab + Trastuzumab + Capecitabine/Cisplatin (HER2 positive ARM) as first line therapy in…
- Trial name
- NCT04249739
- Testing
- Pembrolizumab
- Where
- South Korea
- Volunteers
- 93 people
- Sponsor
- Samsung Medical Center
Metastatic Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
The purpose of this study is to evaluate the efficacy and safety of selinexor alone or with pembrolizumab in participants with advanced or metastatic colorectal cancer (CRC).
- Trial name
- NCT04854434
- Testing
- Selinexor, Pembrolizumab, Trifluridine
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Karyopharm Therapeutics Inc
Neuroendocrine Tumors
Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma
This is an open label, non-randomized phase 2 study to assess overall response rate (ORR), clinical benefit rate (CBR), overall survival (OS) and progression free survival (PFS) in patients with high grade neuroendocrine tumors…
- Trial name
- Pembro NEC (NCT03190213)
- Testing
- Pembrolizumab Injection
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Utah
Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment.
- Conditions
- Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8
- Trial name
- NCT04164082
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 390 sites in United States, Guam and 1 more
- Volunteers
- 161 people
- Sponsor
- National Cancer Institute (NCI)
Head & Neck Squamous Cell Carcinoma
Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)
phase II, randomized, double-blind, placebo controlled, non pharmacological clinical trial that aims to determine the effect of postbiotics Postbiotix-HLA™ on immuno-related adverse events (irAEs) in patients with…
- Trial name
- POST-BIO (NCT07485296)
- Testing
- Postbiotix-HLA™ is a food supplement based on fermented FOS from Lactobacillus paracasei CNCM I-5220 postbiotic., Pembolizumab
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Melanoma
The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)
Background: The gut microbiome is made up microorganisms. These include the good and bad bacteria that live in the digestive tract. Changes in the gut microbiome have been linked to the development of cancer.
- Trial name
- NCT04866810
- Testing
- Intervention Arm, Control
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Pancreatic Ductal Adenocarcinoma
BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Single-arm, open label study to determine the 18 week progression-free survival rate of the combination of BXCL701 and pembrolizumab in patients with pancreatic ductal adenocarcinoma in the second-line metastatic setting.
- Trial name
- EXPEL PANC (NCT05558982)
- Testing
- BXCL701, Pembrolizumab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Georgetown University
Metastatic Solid Tumors, Non-small Cell Lung Cancer
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination…
- Conditions
- Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- PDL1x41BB (NCT03809624)
- Testing
- INBRX-105 - PDL1x41BB antibody, Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Inhibrx Biosciences, Inc
Mesothelioma
A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma
The investigators propose to ensure a favorable gut microbiome by fecal microbiota transplant to enhance the efficacy Keytruda
- Trial name
- NCT04056026
- Testing
- Fecal Microbiota Transplant
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- ProgenaBiome
Non-small Cell Lung Cancer
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (RO7247669) in combination with platinum-based chemotherapy compared with pembrolizumab plus platinum-based chemotherapy in…
- Trial name
- NCT05775289
- Testing
- Tobemstomig, Pembrolizumab, Paclitaxel
- Where
- 50 sites in United States, Australia and 9 more
- Volunteers
- 182 people
- Sponsor
- Hoffmann-La Roche
Resectable Liposarcoma, Resectable Soft Tissue Sarcoma
Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall
This phase III trial compares the effect of adding doxorubicin and ifosfamide (AIM chemotherapy) before (neoadjuvant) receiving standard treatment with pembrolizumab, radiation therapy and surgery to standard of care treatment…
- Conditions
- Resectable Liposarcoma, Resectable Soft Tissue Sarcoma, Resectable Undifferentiated Pleomorphic Sarcoma
- Trial name
- NCT07823491
- Testing
- Biospecimen Collection, Computed Tomography, Doxorubicin
- Where
- United States
- Volunteers
- 228 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Solid Tumor, Lymphoma
RPTR-147 in Patients With Selected Solid Tumors and Lymphomas
The purpose of this study is to assess the safety and tolerability of escalating doses of RPTR-147 as a monotherapy and in combination with Pembrolizumab in patients with selected solid tumors and lymphomas.
- Trial name
- NCT03815682
- Testing
- Arm A: RPTR-147:1, Arm B: RPTR-147:1 and Pembrolizumab, Arm C: RPTR-147:2
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- Repertoire Immune Medicines
Adenoid Cystic Carcinoma, Salivary Gland Cancer
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
The purpose of this study is to see if the study drugs, lenvatinib and pembrolizumab, are effective in treating advanced Adenoid Cystic Carcinoma (ACC) or other salivary gland cancers that have come back and/or spread to other…
- Trial name
- NCT04209660
- Testing
- Lenvatinib, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 64 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Classical Hodgkin Lymphoma
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
This phase II trial studies the side effects of doxorubicin hydrochloride, pembrolizumab, vinblastine, and dacarbazine in treating patients with classical Hodgkin lymphoma.
- Trial name
- NCT03331341
- Testing
- Dacarbazine, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Non-Small Cell Lung Cancer
Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients
This is a Phase 1/2, multi-center, open-label, dose-escalation trial of Ad-MAGEA3 and MG1-MAGEA3 in combination with pembrolizumab in patients with Non-Small Cell Lung Cancer who have completed a first standard therapy with at…
- Trial name
- NCT02879760
- Testing
- Ad-MAGEA3, MG1-MAGEA3, Pembrolizumab
- Where
- 6 sites in Canada
- Volunteers
- 16 people
- Sponsor
- Turnstone Biologics, Corp.
Lung Cancer, Non-Small Cell
Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
NSCLC comprises of approximately 84 percent (%) of all lung cancers and is often diagnosed at advanced stage due to poor prognosis.
- Trial name
- NCT04581824
- Testing
- Dostarlimab, Pembrolizumab, Chemotherapy
- Where
- 58 sites in United States, Argentina and 10 more
- Volunteers
- 243 people
- Sponsor
- GlaxoSmithKline
A Single Patient Will be Treated With Individual Patient TCR-Transduced PBL
A single patient will be treated with Individual Patient TCR-Transduced PBL
- Trial name
- NCT04194190
- Testing
- Individual Patient TCR-Transduced PBL
- Sponsor
- National Institutes of Health Clinical Center (CC)
Kaposi Sarcoma, Progression, Disease
Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi's Sarcoma
Classic and endemic Kaposi's sarcoma (KS) are lymphangio-proliferations associated with human herpes virus 8 (HHV8), which treatment is poorly codified. Chemotherapies give at best 30-60% of transient responses.
- Trial name
- KAPKEY (NCT03469804)
- Testing
- Pembrolizumab
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Head and Neck Cancer Squamous Cell Carcinoma
A Clinical Trial Comparing an Antibody (INCA33890) Versus Pembrolizumab for Squamous Cell Carcinoma of the Head and Neck.
The objective of this research is to evaluate the efficacy of the new drug INCA33890 compared to the standard reference treatment, pembrolizumab. The study treatment is INCA33890. The reference treatment is pembrolizumab.
- Trial name
- TRACE (NCT07876414)
- Testing
- INCA33890, Pembrolizumab
- Volunteers
- 78 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.